Being cut may be the best thing?

Quote


















If you get cut it will be the best thing for you but you might not feel that way at first. I was in the group that got cut 2 yrs ago and was looking forward to it so I could get away from this company. It worked out for me and will work out for those that get cut this time. You will find a real company that acts like a company and is run like a company should be run.

To those that do get cut my sympathies. There are still a few of you there that I worked with. There is a much better opportunity around the corner. I know because I have that now.
 






from the Neuro board

When a major blockbuster loses patent protection, generic competition leaves a gaping hole in the top line, abruptly changing a company's greatest strength into its greatest liability. Let's take a closer look at five blockbuster drugs that will lose patent protection in 2014, and how four companies -- Teva Pharmaceutical (NYSE: TEVA ) , Eli Lilly (NYSE: LLY ) , Novartis (NYSE: NVS ) , and AstraZeneca (NYSE: AZN ) -- will be affected.

Terrible days ahead for Teva
Teva Pharmaceutical is best known for its generics business, but also owns a sizable large specialty pharmaceuticals business that accounts for 42% of its revenue.

Teva's biggest drug in its specialty portfolio is Copaxone, a blockbuster multiple sclerosis drug that generated $1.05 billion in sales last quarter -- half of the specialty pharma segment's revenue and 20% of Teva's total top line. Over the past four years, sales of Copaxone have steadily risen as the primary pillar of growth for Teva's top line.


Source: Company annual reports.

However, Teva's key patent for Copaxone will expire in May 2014, opening the doors for generic competition. Mylan and Momenta Pharmaceuticals have already stated that their intent to release generic versions the moment Teva's patent expires. Generic Copaxone would be an excellent development for MS patients, who pay $40,000 for the drug annually, but it could be devastating to Teva's top line.


GET A NEW JOB NOW
 






Anonymous said:
Looks like the illegal activity surrounding Aggrenox will end WH for good by this time next year.
Click to expand...

I am surprised that a whistleblower lawsuit has not surfaced related to aggrenox. I wonder, under subpoena, how many reps actually made aggrenox calls with targeted physicians as required by contract. I wonder how many reps under subpoena would admit they truely made over 100 niaspan and aggrenox calls in one quarter AND met their own product required metrics? How many reps were told to "check the box" to meet those quarter call requirements?

Didn't you love Brian s west abd present chart data showing all those wonderful metrics and seeing those aggrenox calls totaling more than our own product calls and he stating great job? If you did not, Brian should still have that slide because those docs should have been retained.

From what I saw, contract fraud was committed by TWH against B.I. TWH is over.
 






Aggrenox said:
I am surprised that a whistleblower lawsuit has not surfaced related to aggrenox. I wonder, under subpoena, how many reps actually made aggrenox calls with targeted physicians as required by contract. I wonder how many reps under subpoena would admit they truely made over 100 niaspan and aggrenox calls in one quarter AND met their own product required metrics? How many reps were told to "check the box" to meet those quarter call requirements?

Didn't you love Brian s west abd present chart data showing all those wonderful metrics and seeing those aggrenox calls totaling more than our own product calls and he stating great job? If you did not, Brian should still have that slide because those docs should have been retained.

From what I saw, contract fraud was committed by TWH against B.I. TWH is over.
Click to expand...



B.I. is in on it. Pay to Delay is what they are doing. No one has a co-promote with a GENERIC COMPANY and the women's health part of the company to promote Aggrenox to OB/GYNs. Even a novice would know this smells of illegal activity. B.I. paid us to not bring a generic to market. Tsk, tsk, tsk. This company knows better. The FDA would love a phone call. How many with us have been told and coerced to make up fake calls? Everyone has. All of us. Numerous times. By all levels of management. Ed knows it. The ABDs know it. After this last lay off where they lied to all the managers for months, someone should make a call. That's all it will take.
 






Know what's interesting? I made niaspan calls and was never trained or signed off on niaspan. Isn't that a violation of FDA laws? Never thought about it until now, just "mark the box" as told.
 










































Top Bottom
Back
Quote